Literature DB >> 17554105

Preserved fertility in a non-mosaic Klinefelter patient with a mutation in the fibroblast growth factor receptor 3 gene: case report.

A Juul1, L Aksglaede, A M Lund, M Duno, N E Skakkebaek, E Rajpert-De Meyts.   

Abstract

Patients with Klinefelter syndrome (47,XXY) are characterized by eunuchoid body proportions, gynaecomastia, small firm testes and azoospermia. We describe a Klinefelter patient (non-mosaic 47,XXY karyotype) who was heterozygous for the classical 1138G>A mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, which is a gain-of-function mutation resulting in achondroplasia. The patient had phenotypic characteristics of achondroplasia (e.g. short limbed dwarfism and frontal bossing). Testicular volume was 8 ml at 27 years of age and repeated semen samples showed sperm concentrations of 0.175 million/ml. Serum FSH levels were elevated (21.7 IU/l) compared to normal age-matched healthy male controls and patients with non-mosaic Klinefelter syndrome, and inhibin B levels were low-normal, in contrast to the usually undetectable inhibin B levels in adult Klinefelter patients. The patient fathered a child from a spontaneous pregnancy. The observed testicular size and function in our patient contrast the typical findings in classical Klinefelter syndrome. We speculate that the alteration of FGFR3 protein function in our Klinefelter patient alleviated the destruction of the seminiferous tubules and may suggest that the fibroblast growth factor family has a pleiotrophic function in human spermatogonia, which physiologically express FGFR3.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17554105     DOI: 10.1093/humrep/dem126

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Fibroblast growth factor receptor 3 is highly expressed in rarely dividing human type A spermatogonia.

Authors:  Kathrein von Kopylow; Hannah Staege; Wolfgang Schulze; Hans Will; Christiane Kirchhoff
Journal:  Histochem Cell Biol       Date:  2012-07-10       Impact factor: 4.304

Review 2.  Human spermatogonial stem cells: a possible origin for spermatocytic seminoma.

Authors:  R Waheeb; M-C Hofmann
Journal:  Int J Androl       Date:  2011-08

Review 3.  Paternal age effect mutations and selfish spermatogonial selection: causes and consequences for human disease.

Authors:  Anne Goriely; Andrew O M Wilkie
Journal:  Am J Hum Genet       Date:  2012-02-10       Impact factor: 11.025

4.  Visualizing the origins of selfish de novo mutations in individual seminiferous tubules of human testes.

Authors:  Geoffrey J Maher; Simon J McGowan; Eleni Giannoulatou; Clare Verrill; Anne Goriely; Andrew O M Wilkie
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

5.  Achondroplasia with 47, XXY karyotype: a case report of the neonatal diagnosis of an extremely unusual association.

Authors:  Purificación Ros-Pérez; Francisco J Regidor; Esmeralda Colino; Cristina Martínez-Payo; Eva Barroso; Karen E Heath
Journal:  BMC Pediatr       Date:  2012-06-29       Impact factor: 2.125

6.  New evidence for positive selection helps explain the paternal age effect observed in achondroplasia.

Authors:  Deepali N Shinde; Dominik P Elmer; Peter Calabrese; Jérôme Boulanger; Norman Arnheim; Irene Tiemann-Boege
Journal:  Hum Mol Genet       Date:  2013-06-04       Impact factor: 6.150

7.  Prenatal diagnosis of concurrent achondroplasia and klinefelter syndrome.

Authors:  Esther Perez-Carbajo; Ignacio Zapardiel; Luis Sanfrutos-Llorente; Sara Cruz-Melguizo; Cristina Martinez-Payo; Enrique Iglesias-Goy
Journal:  Case Rep Obstet Gynecol       Date:  2015-02-18

8.  Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.

Authors:  Anne Goriely; Ruth M S Hansen; Indira B Taylor; Inge A Olesen; Grete Krag Jacobsen; Simon J McGowan; Susanne P Pfeifer; Gilean A T McVean; Ewa Rajpert-De Meyts; Andrew O M Wilkie
Journal:  Nat Genet       Date:  2009-10-25       Impact factor: 38.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.